DWTX, US92829J2033

Dogwood Therapeutics stock gained 2.10 percent on October 2

Published on 10/05/2026 at 12:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Dogwood Therapeutics stock is tied to a 239-patient Halneuron trial due for topline data in November 2026. Q2 net loss reached USD 11.5 million.

DWTX, US92829J2033, Illustration mit AI erstellt.

Dogwood Therapeutics stock (ISIN US92829J2033) was last at USD 1.46 on Nasdaq on October 2, 2026, up 2.10 percent from the prior close. The company is approaching a clinical milestone after enrolling 239 patients in its Halneuron Phase 2b trial, according to Dogwood Therapeutics on September 14, 2026.

Halneuron reaches 239 patients

The enrollment total reached the upper end of the company's planned target range, while the randomized Phase 2b study compares Halneuron with placebo in chemotherapy-induced neuropathic pain. The trial uses eight subcutaneous doses over 14 days and follows participants for 28 days, according to Dogwood Therapeutics.

Topline data are expected in November 2026. The study's primary endpoint measures the change in weekly average daily pain intensity from baseline to week four, making the clinical readout more important than enrollment alone for the stock's next fundamental reassessment.

Losses frame the data milestone

Dogwood remains a development-stage biotechnology company with no commercial product revenue. Quartr reported a Q2 2026 net loss of USD 11.5 million as the chemotherapy-induced neuropathic pain trial neared completion, and described the cash runway as extending into Q4 2026, in a September 11, 2026 corporate presentation summary from Quartr.

Analyst expectations are materially higher than the share price. MarketScreener lists a Buy consensus from 2 analysts with an average target of USD 14.00, while The Globe and Mail reported on October 2, 2026, that H.C. Wainwright reiterated a Buy rating with a USD 12.00 price target. The average target lies 858.9 percent above the October 2 price, a gap that reflects both clinical optionality and substantial execution risk.

Stock remains below yearly high

DWTX's October 2 market capitalization was USD 49.1 million, with volume of 71,089 shares. The 52-week range was USD 1.28 to USD 7.20, placing the last price 79.7 percent below the high and 14.1 percent above the low.

The stock's next major company-specific checkpoint is the November 2026 Halneuron data readout. Until then, the valuation debate turns on whether the Phase 2b results can support further development while the quarterly loss remains substantial.